ArticleClinical rheumatology2026
Relapse risk after glucocorticoid withdrawal in stable Sjögren's disease-associated interstitial lung disease: a retrospective cohort study in China.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the risk of relapse after glucocorticoids (GCs) withdrawal in patients with stable Sjögren's disease-associated interstitial lung disease (SjD-ILD).
methodsThis was a single-center, retrospective cohort study conducted at Peking Union Medical College Hospital between February 2016 and January 2024. The study compared two treatment strategies for patients with stable SjD-ILD: GC withdrawal versus GC maintenance. The primary endpoint was to compare the relapse rates between the two groups over a 3-year follow-up period. The secondary endpoints included changes in pulmonary function, serological markers, and adverse events.
resultsA total of 134 patients were included in this study, with 61 in the GC withdrawal group and 73 in the GC maintenance group. Over the 3-year follow-up, 16 patients (27.93%) in the withdrawal group and 19 patients (28.77%) in the maintenance group experienced a relapse. No significant difference was found in relapse rates between the two groups (HR = 1.011, 95% CI 0.517-1.977, p = 0.974). Changes in pulmonary function, ESR, hs-CRP, C3, and C4 levels showed no significant differences, while IgG changes differed at the 2- and 3-year follow-up (p < 0.05). Adverse event rates were similar between groups.
conclusionsGCs' withdrawal in patients with stable SjD-ILD did not increase the relapse risk compared to continuing low-dose GCs' therapy. These findings suggest that cautious GCs' withdrawal might be a viable option for patients with stable, clinically inactive SjD-ILD. Key Points • Glucocorticoid withdrawal in stable pSS-ILD did not increase relapse risk compared to continuing low-dose GC therapy.
Indexed as
Identifiers
41492016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.